Rheumatology Therapeutics Market to Hit a Valuation of US$ 38.34 Billion by 2033 | Astute Analytica
View original at globenewswire.comRheumatology Therapeutics Market to Hit a Valuation of US$ 38.34 Billion by 2033 | Astute Analytica Chicago, Nov…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The median annual cost for biologics facing biosimilar competition has dropped to USD 23,700
80% confidenceProjections for 2025 warn of a deficit of 2,576 adult rheumatologists needed to match patient volume
80% confidenceAbbVie has officially confirmed guidance of USD 16.5 billion in global sales for Skyrizi alone in 2025
80% confidenceEast and South Asia reported a staggering 4.8 million diagnosed rheumatoid arthritis cases in 2024
80% confidenceBiosimilar prescriptions surged to account for nearly 1 in 4 adalimumab scripts, totaling approximately 250,000 following CVS Caremark formulary removal of Humira
80% confidenceRevenue guidance for Rinvoq has been raised to USD 8.2 billion for 2025
80% confidenceThe average annual cost for Medicare patients on biologics stood at USD 36,053 in 2024
80% confidenceThe global rheumatology therapeutics market was valued at US$ 28.75 billion in 2024 and is expected to reach US$ 38.34 billion by 2033, witnessing a CAGR of 3.4% during the forecast period 2025-2033
80% confidenceThe Asia-Pacific region tracks 3.2 million RA cases
80% confidence72 out of every 100 US counties have zero clinically active rheumatologists
80% confidenceVagus Nerve Stimulation trial reported 35 out of 100 patients achieving statistically significant responses
80% confidence78 million Americans will carry an arthritis diagnosis by 2040
80% confidenceUninsured or unresponsive patients face up to USD 30,000 annually in out-of-pocket costs
80% confidenceMainland China accounted for 58 of every 100 new rheumatology trials initiated in 2024
80% confidenceBiologics without biosimilar competition maintain a median cost of USD 42,527
80% confidence87 patients achieved substantial ACR50 improvement in ivarmacitinib trial compared to just 29 in the placebo group
80% confidenceMore than 75 key pharmaceutical companies have registered active clinical programs in 2024 alone
80% confidenceOver 80 distinct therapies for rheumatoid arthritis are currently in active development pipelines
80% confidence18 million new cases of rheumatoid arthritis were identified globally in 2024
80% confidence59 out of 100 patients on Abatacept achieved ACR50 in the AMPLIFIED trial, demonstrating efficacy on par with Adalimumab
80% confidenceThe Sandoz-produced adalimumab-adaz captured 55.5% of all biosimilar prescriptions
80% confidenceWhile 29 out of 100 high-risk placebo patients developed RA, only 9 out of 100 in the methotrexate treatment arm progressed to the disease
80% confidenceOver a five-year span, the average sales price of rheumatology biosimilars has decreased by USD 2,200
80% confidenceThe US currently relies on just 5,667 clinically active rheumatologists
80% confidenceIn the IVARMACITINIB trial, 133 out of 189 patients successfully achieved an ACR20 response
80% confidence93 out of 100 rural jurisdictions lack a single rheumatology provider
80% confidenceHigh-dose arms of major 2024 JAK-1 inhibitor trials reported 0 systemic opportunistic infections
80% confidenceNorth America holds 41% of the global rheumatology therapeutics revenue share
80% confidenceSkyrizi and Rinvoq together are targeted to exceed USD 25 billion in sales in 2025, effectively surpassing the historical peak revenues of Humira
80% confidence50% of the current rheumatology workforce is aged over 55, signaling an impending retirement cliff
80% confidence